Connect your AI

Ardelyx ARDX Change in Lease Liabilities

Change in Lease Liabilities at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

-$434K-23.3%

Aurinia PharmaceuticalsAUPH

-$214K-9.7%

Agios PharmaceuticalsAGIO

-$4.46M-10.2%

Other financials

Income statement

Revenue$94.5M+27.5%

Gross profit$89.7M+45.1%

Operating income-$32.8M+9.8%

Net income-$37.6M+8.6%

EPS (diluted)-$0.15+11.8%

Balance sheet

Cash & equivalents$31.2M+1.3%

Total debt$208.3M+34.3%

Total equity$148.6M+2.0%

Total assets$504.5M+23.0%

Cash flow

Operating cash flow-$32.2M+16.2%

CapEx$69.0K-78.8%

Free cash flow-$32.3M+16.7%

Valuation

Market cap$1.53B+79.5%

Enterprise value$1.71B+74.8%

P/S3.6×+1.2×

Profitability

Gross margin92.5%+7.9pp

Operating margin-25.4%—

Net margin-13.6%—

FCF margin-40.9%—

Returns & leverage

Return on equity-39.5%—

Debt / equity1.4×+0.3×

Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ardelyx's change in lease liabilities?: Ardelyx (ARDX) reported change in lease liabilities of -$373K in Q1 2026.
How has Ardelyx's change in lease liabilities changed year-over-year?: Ardelyx's change in lease liabilities increased by 62.4% year-over-year, from -$991K to -$373K.
What is the long-term trend for Ardelyx's change in lease liabilities?: Over 4 years (2021 to 2025), Ardelyx's change in lease liabilities has grown at a -10.5% compound annual growth rate (CAGR), from -$2.85M to -$1.83M.
What does change in lease liabilities mean?: Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.